Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects

European Journal of Endocrinology

Volumn 156, Issue 4, 2007, Pages 503-509

  Gulffanti, Monica ^a   Caumo, Andrea ^b   Galli, Laura ^a   Bigoloni, Alba ^a   Galli, Andrea ^a   Dagba, Geneviéve ^a   Danise, Anna ^a   Luzi, Livio ^b   Lazzarin, Adriano ^a,c   Castagna, Antonella ^a  

^a Raffaela Scientific Institute   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ATAZANAVIR; C PEPTIDE; CHOLESTEROL; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INDINAVIR PLUS RITONAVIR; INSULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PANCREAS ISLET CELL FUNCTION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PYRIDINES; RETREATMENT; TREATMENT OUTCOME;

EID: 34247629373     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0648     Document Type: Article

References (34)

1. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory Washington, DC:US Food and Drug Administration, 1997.
2. Dubè MR Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 2000 31 1467-1475.
3. Bergman RN, Finegood DT & Kahn SE. The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. European Journal of Clinical Investigation 2002 32 35-45.
4. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. Acquired Immunodeficiency Syndrome 1998 12 F167-F173.
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Acquired Immunodeficiency Syndrome 1998 12 F51-F58.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant J, Köner T, Stoll M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Acquired Immunodeficiency Syndrome 1999 13 F63-1370.
7. Woerle H.J., Mariuz PR, Meyer C, Reichman RC, Popa. FM, Dostou JM, Welle SL, Gerich JE, Welle SL & Gerich JE. Mechanism for the deterioration in glucose tolerance associated with HIV protease inhibitor regimen. Diabetes 2003 52 918-925.
8. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M & Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. Acquired Immunodeficiency Syndrome 2001 15 11-18.
9. Dubè MP, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D & Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2001 27 130-134.
10. Noor MA, Seneviratne T, Aweeka FT Lo JC, Schwarz JM, Mulligan K, Schambelan M & Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. Acquired Immunodeficiency Syndrome 2002 16 FI-F8.
11. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M & Grunfeld C. The metabolic effects of lopinavir/ ritonavir in HIV-negative men. Acquired Immunodeficiency Syndrome 2004 18 641-649.
12. Dubè MP, Qian D, Edmondson-Melançon H, Sattler FR, Goodwin D, Martinez C, Williams V, Johnson D & Buchanan TA. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clinical Infectious Diseases 2002 35 475-481.
13. Murata H, Hruz PW & Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 2000 275 20251-20254.
14. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, Wang S, Yang WP & Noor MA. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Molecular Pharmacology 2005 67 1909-1919.
15. Hadigan C, Borgonha S, Rabe J, Young V & Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002 51 1143-1147.
16. Brambilia AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, Castagna A & Lazzarin A. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. Acquired Immunodeficiency Syndrome 2003 17 1193-1195.
17. Swainston Harrison T & Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005 65 2309-2336.
18. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT & Haas DW. The effect of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. Acquired Immunodeficiency Syndrome 2004 18 2137-2144.
19. Noor MA, Flint OP, Maa J-F & Parker RA. Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. Acquired Immunodeficiency Syndrome 2006 20 1813-1821.
20. Möbius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E, Christensen S, Rump J, Fätkenheuer G, Behrens G & Schmidt RE. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. Journal of Acquired Immune Deficiency Syndromes 2005 39 174-180.
21. Malan N, Krantz E, David N, Kastango K, Frederick D, Matthew M, Schnittman S, Hammond J & the -089 Study Group. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 (Abstract 1071B). Presented at: XIII Conference on Retroviruses and Opportunistic Infections. Denver, February 2006.
22. Samson R Rutstein R, Penton T, Kiser J, Pletcher C, Schnittman C, Mofenson L, Smith E, Graham B, Aldrovandi G & PACTG 1020 Study Team. Changes in cholesterol and triglyceride level among pediatric patients treated with atazanavir, with or without ritonavir boosting: the 1020A NTH PACTG Protocol (Abstract 689). Presented at: XIII Conference on Retroviruses and Opportunistic Infections. Denver, February 2006.
23. Grinspoon S & Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005 352 48-62.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
25. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ill). Journal of the American Medical Association 2001 285 2486-2497.
26. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC & Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 1998 47 1643-1649.
27. Aseaso JE Pardo S, Real JT, Lorente RI, Priego A & Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003 26 3320-3325.
28. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003 26 S5-S20.
29. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 2004 27 1487-1495.
30. Caumo A, Bergman RN & Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. Journal of Clinical Endocrinology and Metabolism 2000 85 4396-4402.
31. Mari A, Pacini G, Brazzale AR & Ahrén B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005 48 748-751.
32. Stumvoll M, Van Haeften T, Fritsche A & Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 2001 24 796-797.
33. Stumvoll M, Mitrakou A, Pimenta W Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W & Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000 23 295-301.
34. Noor MA, Flint OP, Parker RA, Maa J, Witek J & Hodder SL. Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): a prospective, randomized study using a hyperinsulinaemic, euglycaemic clamp and oral glucose tolerance testing (Abstract 16). Antiviral Therapy 2005 10 L11.